Issue Date: November 2, 2009
Biotech Companies Make Merger Deals
Ligand Pharmaceuticals will acquire Metabasis Therapeutics by initially paying about $1.8 million to Metabasis stockholders and making future cash payments if it sells or finds partners for any Metabasis drug development programs. Ligand has agreed to spend at least $8 million in new R&D funding on the Metabasis programs within 42 months of closing the deal. In a more traditional merger, BioMarin Pharmaceutical has paid $15 million to acquire Huxley Pharmaceuticals and its amifampridine phosphate drug for treating Lambert Eaton Myasthenic Syndrome, a rare autoimmune disease. BioMarin will make up to $43.5 million in other payments if the drug hits certain milestones.
- Chemical & Engineering News
- ISSN 0009-2347
- Copyright © American Chemical Society